NCT04838405

A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus

A Phase 1 Randomized, Double Blind, Placebo Controlled, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CT-388 in Otherwise Healthy Overweight and Obese Adult Participants and in Obese Patients With Type 2 Diabetes Mellitus

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 129 (actual)
• Sponsor: Carmot Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This is a first-in-human evaluation of CT-388 in a double blind, placebo controlled, randomized, SAD/MAD/MD, safety, tolerance, PK, and PD study when administered as a SC injection in otherwise healthy overweight and obese adult participants and obese participants with T2DM.

Conditions

• Diabetes

Interventions

Type	Name	Description
DRUG	CT-388	Synthetic Peptide
DRUG	Placebo	Placebo

Timeline

• Start date: 2021-04-29
• Primary completion: 2024-06-18
• Completion: 2024-08-02
• First posted: 2021-04-09
• Last updated: 2025-10-20

Locations

2 sites across 2 countries: Australia, Mexico